Cells, PBMC, CD8+ Cytotoxic T cells, Negative Selection, BioPrimary(TM)

BioPrimary(TM) Cells are derived using technology including advanced protocols and adjuvants that ehance the viability of our cells to over >90% total post-thaw viability.\n\nCD8+ cytotoxic killer T cells (CTL) belong to a sub-group of T lymphocytes that are capable of inducing the death of infected-somatic [with viruses or other pathogens] or tumor cells. Most CD8+ cytotoxic T cells express T-cell receptors (TCRs) that can recognize a specific antigenic peptide bound to Class I MHC molecules, present on all nucleated cells, and a glycoprotein called CD8, which is attracted to non-variable portions of the Class I MHC molecule. The affinity between CD8 and the MHC molecule keeps the Cytotoxic T cell and the target cell bound closely together during antigen-specific activation. CD8+ T cells are recognized as Cytotoxic T cells once they become activated and are generally classified as having a pre-defined cytotoxic role within the immune system.\n\nRole in Disease Pathogenesis:\nCD8+ cytotoxic T cells play an important pathogenetic role during Hepatitis B Virus (HBV) infection. These cells eliminate the virus by killing infected cells and producing antiviral cytokines capable of purging HBV from viable hepatocytes. Recently, CTLs have been implicated in the progression of arthritis; specifically in the depletion of knee joint cartilage macromolecules such as glycosaminoglycans.\n\nAll products are shipped on dry ice with: 1) Certificate of Analysis (with viability and purity results), and 2) Thawing instructions\n\nStorage and Stability: \nIt is recommended that cells are used as soon as possible following receipt to ensure optimal viability. Cells may be stored at -80 C for up to one month (minimize storage length at -80 C in order to maximize viability).

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C2600-300

Size

5M Cells

References

1. Sarin, R. et al., Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. PNAS (2011) 108; 9560